Investigators have discovered why Huntington’s disease is so toxic to cancer cells and are harnessing it as a novel approach to treat cancer.
Browsing: emerging therapies
The American Society of Clinical Oncology (ASCO) has named adoptive cell immunotherapy as their clinical cancer Advance of the Year.
Discover the biggest stories of 2018 ASCO-SITC in our conference news round-up.
Findings presented at the 2018 ASCO-SITC symposium highlight initial success for a new form of CAR T-cell treatment.
A PGE2-receptor type-4 inhibitor, termed E7046, has demonstrated promising clinical activity in a Phase I trial of patients with advanced solid tumors.
A new drug, termed ixazomib, is to be used in combination with standard treatments and has been made available on the Cancer Drug Fund.
Over the past decade immunotherapy has revolutionized oncology, however, only a small percentage of patients currently benefit. Discover several of the hurdles that need to be tackled to make immunotherapy available to more cancer patients.
Discover the case of a heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix who had exhausted all available treatments and demonstrated a striking response to pembrolizumab.
Right now, doctors can’t tell whether women with DCIS will go on to develop breast cancer. This means that, unfortunately, some women with DCIS undergo unnecessary treatment. Find out how Jelle and his team are looking to change this.
Researchers have discovered that anti-PD-1/PD-L1 therapies are highly effective in patients with desmoplastic melanoma, challenging previous assumptions.